**Appendix Table D30. Migraine frequency, severity, and drug utilization with valproate vs. placebo for migraine prevention in adults, results from medium risk of bias randomized controlled clinical trials**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome** | **Daily Dose** | **Reference** | **Mean [Standard deviation]**  **with Valproate** | **Mean [Standard deviation]**  **with Placebo** | **Randomized to Valproate**  **vs. Placebo** | **Mean Difference**  **(95% CI)** | **Cohen Standardized Mean**  **Difference**  **(95% CI)** |
| Mean number of days with migraine | 1000mg to 1500 mg per day | Jensen, 199449 | 3.5 [4.8] | 6.1 [7.7] | 43 [43] | -2.6 (-5.3 to 0.1) | -0.4  (-0.8 to 0.0) |
| **Total drug consumption** | **1000mg to 1500 mg per day** | Jensen, 199449 | **NR [NR]** | **NR [NR]** | **43 [43]** | **p value <0.001** |  |
| Consumption of symptomatic medication per attack | 1000mg to 1500 mg per day | Jensen, 199449 | NR [NR] | NR [NR] | 43 [43] | p value 0.61 |  |
| **Mean number of attacks (4 weeks)** | **400 mg twice a day** | Hering, 199248 | **8.8 [6.1]** | **15.6 [8.3]** | **32 [32]** | **-6.8 (-10.3 to -3.2)** | **-0.9**  **(-1.4 to -0.4)** |
| Duration of the remaining attack (hours) | 1000mg to 1500 mg per day | Jensen, 199449 | 11.1 [NR] | 11.5 [NR] | 43 [43] | p value 0.9 |  |
| **Duration of the attack (total hours)** | **400 mg twice a day** | Hering, 199248 | **1731.0 [NR]** | **2789.0 [NR]** | **32 [32]** | **p value = 0.002** |  |
| Intensity of the remaining attacks (no details provided) | 1000mg to 1500 mg per day | Jensen, 199449 | 2.3 [NR] | 2.3 [NR] | 43 [43] | p value0.45 |  |
| **Mean number of severe migraine attacks (4 weeks)** | **400 mg twice a day** | Hering, 199248 | **14.6 [9.8]** | **24.0 [15.4]** | **32 [32]** | **-9.4 (-15.7 to -3.1)** | **-0.7**  **(-1.2 to -0.2)** |

Bold = significant at 95% confidence limit when 95% CI of mean difference estimates do not include 0

CI = confidence level

NR = not reported